Get the Stockscreener App
10.04
0.05%
0.005
Translational Development Acquisition Corp stock is traded at $10.04, with a volume of 69,900.
It is up +0.05% in the last 24 hours and up +32.81% over the past month.
Translational Development Acquisition Corp is a newly organized blank check company.
See More
Previous Close:
$10.03
Open:
$10.03
24h Volume:
69,900
Relative Volume:
2.14
Market Cap:
$219.95M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.15%
1M Performance:
+32.81%
6M Performance:
+20.48%
1Y Performance:
+0.00%
1-Day Range:
$10.03
$10.04
1-Week Range:
$10.02
$10.04
52-Week Range:
$10.00
$10.04
Translational Development Acquisition Corp Stock (TDAC) Company Profile
Name
Translational Development Acquisition Corp
Sector
Industry
Phone
-
Address
-
Compare TDAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TDAC
Translational Development Acquisition Corp
|
10.04 | 219.95M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
8.41 | 2.45B | 3.13B | 50.80M | 555.00M | 0.1772 |
|
AACT
Ares Acquisition Corporation Ii
|
11.07 | 691.31M | 0 | 16.92M | -1.35M | 0.29 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.57 | 455.83M | 0 | 1.30M | 0 | 0.0301 |
|
AAM
Aa Mission Acquisition Corp
|
10.21 | 448.97M | 0 | 0 | 0 | 0.00 |
|
EQV
Eqv Ventures Acquisition Corp
|
10.02 | 446.39M | 0 | 0 | 0 | 0.00 |
Translational Development Acquisition Corp Stock (TDAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-21-21 | Initiated | Northland Capital | Outperform |
Translational Development Acquisition Corp Stock (TDAC) Latest News
Translational Development Acquisition Corp. Announces that the Separate Trading of its Class A Ordinary Shares and Warrants has Commenced - Yahoo Finance
Major SPAC Update: TDACU Splits Units into Separate Shares & Warrants Trading - StockTitan
Trident Acquisitions stock hits 52-week high of $10.08 By Investing.com - Investing.com Australia
Trident Acquisitions stock hits 52-week high of $10.08 - Investing.com
ImmuPharma (LON:IMM) Stock Price Up 9.3% – Here’s Why - Defense World
TDACU stock touches 52-week low at $10 amid market challenges - Investing.com
TDACU stock touches 52-week low at $10.01 amid market shifts - Investing.com UK
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Yearend 2024 SPAC Market Update & Outlook - Business Wire
Translational Development (TDACU) Raises $172.5M in Successful Nasdaq IPO, Begins Trading - StockTitan
Translational Development Acquisition Corp Launches $150M IPO on Nasdaq, Units to Trade as TDACU - StockTitan
Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board - Business Wire
Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel - GlobeNewswire
IPO NewsUS IPO Weekly Recap: Sizable tech and biotech IPOs are joined by a flurry of small names - Renaissance Capital
(PDF) Measuring Translation Competence Acquisition - ResearchGate
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines - Business Wire
Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer - PR Newswire
Novo Nordisk Expands Boston Area Research and Early Development - Genetic Engineering & Biotechnology News
Merck to Acquire Caraway Therapeutics, Inc. - Business Wire
Locks on Translation Initiation May Restrain Cancer - Genetic Engineering & Biotechnology News
FirstEnergy issues earnings report - 69News WFMZ-TV
Zura Bio Announces Appointment of Chief Scientific Officer - Business Wire
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer - Business Wire
Special Purpose Acquisition Company (SPAC) News and Analysis - SPACInsider
Translation regulatory factor BZW1 regulates preimplantation embryo development and compaction by restricting global non-AUG Initiation - Nature.com
A Stone Capital-backed SPAC braves the blank check waters, looking to grab a $150M deal - Endpoints News
Gate Neurosciences Emerges from Stealth with a Portfolio of Next-Generation Therapies for Central Nervous System Diseases - Business Wire
Oak Hill Bio Appoints Tauhid Ali as First Chief Executive Officer - Business Wire
Quotient integrates drug substance into platform - Speciality Chemicals Magazine
Third Rock Ventures Announces Promotion of David Kaufman, M.D., Ph.D., to Partner - Business Wire
Research and Development grant cheat sheet - University of Sydney
A red blood cell disease meets a company with a plasma protein heritage - Nature.com
BioSpace Movers & Shakers, March 19 - BioSpace
Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc. - Business Wire
BioSpace Movers & Shakers: MoMa Therapeutics, Cerevance, Glympse Bio and More - BioSpace
Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio - Business Wire
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development - The Lancet
Bristol-Myers Squibb's $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert - GeekWire
Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy - Business Wire
Takeda Takes Stake, Inks Deal With Newly Launched Izana Bioscience - BioSpace
Quotient Clinical’s second U.S. acquisition in a row: Charles River’s QS Pharma - Fierce Biotech
What You Need to Know About Denali - BioSpace
Three Former Genentech Researchers Launch Neuroscience Company Denali Therapeutics With $217 Million - BioSpace
People - Nature.com
Translational Development Acquisition Corp Stock (TDAC) Financials Data
There is no financial data for Translational Development Acquisition Corp (TDAC). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.44%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):